Tysabri risk causing headache for companies. [electronic resource]
Producer: 20051007Description: 703-4 p. digitalISSN:- 1474-1776
- Adverse Drug Reaction Reporting Systems -- ethics
- Antibodies, Monoclonal -- adverse effects
- Antibodies, Monoclonal, Humanized
- Autoimmune Diseases -- chemically induced
- Drug Industry -- ethics
- Graft Rejection -- prevention & control
- Humans
- Leukoencephalopathy, Progressive Multifocal -- chemically induced
- Multiple Sclerosis -- complications
- Natalizumab
- Risk Assessment -- ethics
- United States
- United States Food and Drug Administration -- legislation & jurisprudence
No physical items for this record
Publication Type: News
There are no comments on this title.
Log in to your account to post a comment.